The lignan niranthin poisons Leishmania donovani topoisomerase IB and favours a Th1 immune response in mice

EMBO Molecular Medicine

Volumn 4, Issue 10, 2012, Pages 1126-1143

  Chowdhury, Sayan ^a   Mukherjee, Tulika ^a   Mukhopadhyay, Rupkatha ^a   Mukherjee, Budhaditya ^a   Sengupta, Souvik ^a   Chattopadhyay, Sharmila ^a   Jaisankar, Parasuraman ^a   Roy, Syamal ^a   Majumder, Hemanta K ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

Antimony resistance; Chemotherapy; Leishmania donovani; Niranthin; Topoisomerase

Indexed keywords

DNA TOPOISOMERASE; LIGNAN; MULTIDRUG RESISTANCE PROTEIN; NIRANTHIN; NITRIC OXIDE; TYPE IB TOPOISOMERASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; LEISHMANIA DONOVANI; LEISHMANIASIS; MOUSE; NONHUMAN; PARASITE CLEARANCE; PRIORITY JOURNAL; TH1 CELL;

ANIMALS; ANISOLES; ANTIPROTOZOAL AGENTS; CELLS, CULTURED; DIOXOLES; DISEASE MODELS, ANIMAL; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; FEMALE; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIVER; MACROPHAGES; MICE; MICE, INBRED BALB C; NITRIC OXIDE; PARASITE LOAD; PHYLLANTHUS; SPLEEN; TH1 CELLS; TH2 CELLS;

EID: 84867064541     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.201201316     Document Type: Article

References (54)

1. Acharya BR, Bhattacharyya B, Chakrabarti G (2008) The natural naphthoquinone plumbagin exhibits antiproliferative activity and disrupts the microtubule network through tubulin binding. Biochemistry 47: 7838-7845
2. Alexander J, Carter KC, Al-Fasi N, Satoskar A, Brombacher F (2000) Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur J Immunol 30: 2935-2943
3. Ashutosh, Sundar S, Goyal N (2007) Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol 56: 143-153
4. Awasthi A, Mathur RK, Saha B (2004) Immune response to Leishmania infection. Indian J Med Res 119: 238-258
5. Banerjee A, De M, Ali N (2008) Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses. J Immunol 181: 1386-1398
6. Basu R, Bhaumik S, Basu JM, Naskar K, De T, Roy S (2005) Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol 174: 7160-7171
7. Bodley AL, Shapiro TA (1995) Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania. Proc Natl Acad Sci USA 92: 3726-3730
8. BoseDasgupta S, Das BB, Sengupta S, Ganguly A, Roy A, Dey S, Tripathi G, Dinda B, Majumder HK (2008) The caspase-independent algorithm of programmed cell death in Leishmania induced by baicalein: the role of LdEndoG, LdFEN-1 and LdTatD as a DNA 'degradesome'. Cell Death Differ 15: 1629-1640
9. Carvalho EM, Bacellor O, Brownell C, Regis T, Coffman RL, Reed SG (1994) Restoration of IFN-γ production and lymphocyte proliferation in visceral leishmaniasis. J Immunol 152: 5949-5956
10. Carvalho EM, Badaró R, Reed SG, Jones TC, Johnson WD, Jr (1985) Absence of gamma interferon and interleukin-2 production during active visceral leishmaniasis. J Clin Invest 76: 2066-2069
11. Champoux JJ (2001) DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70: 369-413
12. Chowdhury S, Mukherjee T, Sengupta S, Chowdhury SR, Mukhopadhyay S, Majumder HK (2011) Novel betulin derivatives as antileishmanial agents with mode of action targeting type IB DNA topoisomerase. Mol Pharmacol 80: 694-703
13. Coffman RL, Lebman DA, Rothman P (1993) Mechanism and regulation of immunoglobulin isotype switching. Adv Immunol 54: 229-270
14. Das BB, Sen N, Ganguly A, Majumder HK (2004) Reconstitution and functional characterization of the unusual bi-subunit type I DNA topoisomerase from Leishmania donovani. FEBS Lett 565: 81-88
15. Das BB, Sen N, Roy A, Dasgupta SB, Ganguly A, Mohanta BC, Dinda B, Majumder HK (2006) Differential induction of Leishmania donovani bi-subunit topoisomerase I-DNA cleavage complex by selected flavones and camptothecin: activity of flavones against camptothecin-resistant topoisomerase I. Nucleic Acids Res 34: 1121-1132
16. Ding AH, Nathan CF, Stuehr DJ (1988) Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol 141: 2407-2412
17. Fortune JM, Osheroff N (2006) Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol 64: 221-253
18. Gantt KR, Goldman TL, McCornik ML, Miller MA, Jeronimo SM, Nascimento ET, Britigan BE, Wilson ME (2001) Oxidative responses of human and murine macrophages during phagocytosis of Leishmania chagasi. J Immunol 167: 893-901
19. Gangneux JP, Sulahian A, Garin YJ, Farinotti R, Derouin F (1996) Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome. Antimicrob Agents Chemother 40: 1214-1218
20. Ghalib HW, Piuvezam MR, Skeiky YA, Siddig M, Hashim FA, el-Hassan AM, Russo DM, Reed SG (1993) Interleukin 10 production correlates with pathology in human Leishmania donovani. J Clin Invest 92: 324-329
21. Gifawesen C, Farrell JP (1989) Comparison of T-cell responses in self-limiting versus progressive visceral Leishmania donovani infections in golden hamsters. Infect Immun 57: 3091-3096
22. Gordaliza M, Castro MA, del Corral JM, Feliciano AS (2000) Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des 6: 1811-1839
23. Hartmann JT, Lipp HP (2006) Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile. Drug Saf 29: 209-230
24. Huang CY (1982) Determination of binding stoichiometry by the continuous variation method: the Job plot. Methods Enzymol 87: 509-525
25. Huang RL, Huang YL, Ou JC, Chen CC, Hsu FL, Chang C (2003) Screening of 25 compounds isolated from Phyllanthus species for anti-human hepatitis B virus in vitro. Phytother Res 17: 449-453
26. Imbert TF (1998) Discovery of podophyllotoxins. Biochimie 80: 207-222
27. Kassuya CA, Silvestre A, Menezes-de-Lima O, Jr, Marotta DM, Rehder VL, Calixto JB (2006) Antiinflammatory and antiallodynic actions of the lignan niranthin isolated from Phyllanthus amarus. Evidence for interaction with platelet activating factor receptor. Eur J Pharmacol 546: 182-188
28. Kaye P, Scott P (2011) Leishmaniasis: complexity at the host-pathogen interface. Nat Rev Microbiol 9: 604-615
29. Kemp M, Kurtzhals JA, Bendtzen K, Poulsen LK, Hansen MB, Koech DK, Kharazmi A, Theander TG (1993) Leishmania donovani reactive Th1- and Th2 like cell clones from individuals who have recovered from visceral leishmaniasis. Infect Immun 61: 1069-1073
30. Koster DA, Croquette V, Dekker C, Shuman S, Dekker NH (2005) Friction and torque govern the relaxation of DNA supercoils by eukaryotic topoisomerase IB. Nature 434: 671-674
31. Leite DF, Kassuya CA, Mazzuco TL, Silvestre A, de Melo LV, Rehder VL, Rumjanek VM, Calixto JB (2006) The cytotoxic effect and the multidrug resistance reversing action of lignans from Phyllanthus amarus. Planta Med 72: 1353-1358
32. Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351-375
33. Mookerjee Basu J, Mookerjee A, Banerjee R, Saha M, Singh S, Naskar K, Tripathy G, Sinha PK, Pandey K, Sundar S, Bimal S, Das PK, Choudhuri SK, Roy S (2008) Inhibition of ABC transporters abolishes antimony resistance in Leishmania Infection. Antimicrob Agents Chemother 52: 1080-1093
34. Murray MW, Nathan CF (1999) Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J Exp Med 189: 741-746
35. Murugaiyah V, Chan KL (2007) Determination of four lignans in Phyllanthus niruri L. by a simple high-performance liquid chromatography method with fluorescence detection. J Chromatogr A 1154: 198-204
36. Nagill R, Kaur S (2011) Vaccine candidates for leishmaniasis: a review. Int Immunopharmacol 11: 1464-1488
37. Olivier M, Gregory DJ, Forget G (2005) Subversion mechanisms by which Leishmania parasites can escape the host immune response: a signaling point of view. Clin Microbiol Rev 18: 293-305
38. Osheroff N, Shelton ER, Brutlag DL (1983) DNA topoisomerase II from Drosophila melanogaster: relaxation of supercoiled DNA. J Biol Chem 258: 9536-9543
39. Pommier Y (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6: 789-802
40. Rahman M, Ahmed BN, Faiz MA, Chowdhury MZ, Islam QT, Sayeedur R, Rahman MR, Hossain M, Bangali AM, Ahmad Z, Islam MN, Mascie-Taylor CG, Berman J, Arana B (2011) Phase IV trial of miltefosine in adults and children for treatment of visceral Leishmaniasis (Kala-Azar) in Bangladesh. Am J Trop Med Hyg 85: 66-69
41. Reiner NE, Finke JH (1983) Interleukin 2 deficiency in murine leishmaniasis donovani and its relationship to depressed spleen cell responses to phytohemagglutinin. J Immunol 131: 1487-1491
42. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S (2007) Cutaneous leishmaniasis. Lancet Infect Dis 7: 581-596
43. Roach TI, Kiderlen AF, Blackwell JM (1991) Role of inorganic nitrogen oxides and tumor necrosis factor α in killing Leishmania donovani amastigotes in γ interferon-lipopoplysachharide-activated macrophages from Lshs and Lshr congenic mouse strains. Infect Immunol 59: 3935-3944
44. Roy A, Das BB, Ganguly A, Bose Dasgupta S, Khalkho NV, Pal C, Dey S, Giri VS, Jaisankar P, Dey S, Majumder HK (2008) An insight into the mechanism of inhibition of unusual bi-subunit topoisomerase I from Leishmania donovani by 3, 3′-di-indolylmethane, a novel DNA topoisomerase I poison with a strong binding affinity to the enzyme. Biochem J 409: 611-622
45. Saha B, Bandyopadhyay D, Roy S (1995) Immunobiological studies on experimental visceral leishmaniasis. IV. Kinetics of evolution of disease promoting versus host protective cells of monocytes, macrophage lineage and their characterization. Scand J Immunol 42: 540-546
46. Sen N, Das BB, Ganguly A, Mukherjee T, Tripathi G, Bandyopadhyay S, Rakshit S, Sen T, Majumder HK (2004) Camptothecin induced mitochondrial dysfunction leading to programmed cell death in unicellular hemoflagellate Leishmania donovani. Cell Death Differ 11: 924-936
47. Sengupta T, Mukherjee M, Das A, Mandal C, Das R, Mukherjee T, Majumder HK (2005) Characterization of the ATPase activity of topoisomerase II from Leishmania donovani and identification of residues conferring resistance to etoposide. Biochem J 390: 419-426
48. Sharma A, Madhubala R (2001) Ubiquitin conjugation of open reading frame F DNA vaccine leads to enhanced cell-mediated immune response and induces protection against both antimony-susceptible and -resistant strains of Leishmania donovani. J Immunol 166: 4020-4028
49. Stauber AL (1956) Resistance to the Khartoum strain of Leishmania donovani. Rice Inst Pam 45: 80-96
50. Stewart L, Redinbo MR, Qiu X, Hol WG, Champoux JJ (1998) A model for the mechanism of human topoisomerase I. Science 279: 1534-1541
51. Thakur CP, Narayan S (2004) A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis. Ann Trop Med Parasitol 98: 129-138
52. Wang JC (1996) DNA topoisomerases. Annu Rev Biochem 65: 635-692
53. Ward LD (1985) Measurement of ligand binding to proteins by fluorescence spectroscopy. Methods Enzymol 117: 400-414
54. Wortmann G, Zapor M, Ressner R, Fraser S, Hartzell J, Pierson J, Weintrob A, Magill A (2010) Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis. Am J Trop Med Hyg 83: 1028-1033